Sequential sales decline, but order activity has improved* We lift '26e/'27e/'28e EBIT by 9%/7%/6%* 14-11x '26e-'27e EV/EBIT ...
Q3e sales +6%, with 5% organic growth* Raised EBITA driven by new contracts* Share trading at 15x '26e EV/EBITA, goes to 9x ...
Adj. EBITA SEK 57m, 6% below ABGSCe SEK 61m* Organic growth softer than expected* Consensus adj. EBITA revisions likely down ...
Net sales SEK 616m, -1% vs ABGSCe and Factset cons.* EBITA SEK 83m, -6% vs ABGSCe, -4% vs cons* Report moves cons. '26e EBITA ...
Xvivo Perfusion (Q3 Initial take): Strong sales growth, boosted by Thoracic - Redeye ...
Q3e: sequential step-up in organic growth and margin* M&A the main driver behind our EBITA upgrades* Two new acquisitions end ...
ATOSS will release preliminary Q3 figures on Friday. We expect another strong quarter, which should make the margin guidance ...
We lower total ‘27e-‘28e sales by 4%, see break-even in FY'27e* Recycling +66% y-o-y, record trial activity and growing ...
Demand stabilising, but reduction in FTEs a headwind* We cut adj. EBITA by 6% for '26e and 10% for '27e* Trading at ...
EBIT -20% vs. ABGSCe on timing and tech costs* We lower ‘26e-‘28e sales by 3% and EBIT adj. by 4%/6%/5%* EU vote outcome ...
Q3e EBITDA of NOK 10m, top line flat q-o-q* Meijer kicks off the US opportunity* Fair value range of NOK 8-18 per share ...
BofA höjer riktkursen för EQT till 405 kronor, 'undervärderat efter stark kapitalanskaffning' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results